You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. Neuroprotective Drugs for Spinal Cord Injury

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION: (Adapted from the Applicant's Abstract) Traumatic spinal cord injury (SCI) leads to permanent loss of motor function and control of function below the level of the injury. A significant portion of the loss is due to secondary factors rather than the initial trauma. These factors include increased extracellular concentrations of glutamate which ha ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. Neuroadaptive effects after chronic CTDP 31446 treatment

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Cocaine abuse remains a grave concern for the American, and increasingly the world, population. As no current therapeutic agents are available to assist cocaine addicts in achieving and maintaining abstinence it is important that new pharmacotherapies be developed. One important question not usually addressed in the development ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. SOD/Catalase mimics for age-related learning impairment

    SBC: Eukarion, Inc.            Topic: N/A

    DESCRIPTION Adapted from applicant's abstract): Aging is accompanied by a slow decline in cognitive function, now referred to as mild cognitive impairment (MCI), and by accumulation of oxidized proteins and lipids as a result of oxidative stress. Eukarion has discovered a new class of manganese complexes that display both superoxide dismutase (SOD) and catalase ac ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. Aerosolized hyaluronic acid as a treatment for emphysema

    SBC: EXHALE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease afflicts 12-14 million people in the US and in an advanced form, emphysema, disables 2 million and ultimately leads to death. No approved, existing treatment can arrest emphysema's progressive destruction of the lung. Exhale Therapeutics, Inc intends to develop and commercialize aeros ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Standardized Milk Thistle Product

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Standardized Milk Thistle Product

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  8. PET Reagents for Normal and Tumor Tissue Hypoxia

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Disruption of O2 gradients in normal tissues creates major medical problems including cardiovascular disease, stroke, diabetes, liver and kidney damage and organ transplant failure. Steep O2 gradients in tumors protect tumor cells from cytotoxic therapies and create more aggressive tumors. Measurements of O2 gradients are cle ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Molecular Markers for Tissue Hypoxia

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Hypoxia is important in cardiovascular disease and cancer, the two leading causes of death in the US. Studies of these and other diseases need a tool for following changes in tissue hypoxia. We propose the HypoxyprobeTM system of markers can meet this need. HypoxyprobeTM markers have advantages of high water solubility, chemical s ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. Icon Teacher: Stimulus Control Shaping Technology

    SBC: PRAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We request Phase I funding to support development of a prototype product, Icon Teacher, that is intended for certain children who require augmentative/ alternative communication (AAC) intervention. In AAC systems, children who have not learned to speak may indicate wants and needs by responding nonverbally to symbol ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government